1. In Vivo
  2. >>Deal-Making

Despite Pfizer/Seagen’s Splash, Deals Are Staying Small

First Half 2023 Deal-Making Infographic

 
• By Joseph Haas

Although late 2022 and early 2023 saw a few large transactions, a look at deal activity in the first half of the year shows bolt-on M&A remains in vogue for biopharma. Alliances are down from first half 2022.

Year to year comparison
M&A values are up during H1 2023, but skewed by Pfizer/Seagen • Source: Shutterstock

Biopharmaceutical M&A activity started with a bang in 2023, as Pfizer Inc.’s 13 March acquisition of Seagen Inc.  for $43bn was the sector’s largest buyout since a pair of mega-mergers (Bristol Myers Squibb Company/Celgene Corporation and AbbVie Inc./Allergan plc) in 2019. That deal, combined with Merck & Co., Inc.’s $10.8bn deal for Prometheus Biosciences, Inc on 16 April and on the heels of Amgen, Inc.’s $27.8bn acquisition of Horizon Therapeutics plc announced in December 2022, raised hopes that the industry might see more major transactions. But a look at deal statistics for the first half shows that big pharma by and large remains committed to smaller acquisitions.

The cluster of mega-deals drove up aggregate spending on biopharma M&A, which more than doubled the total spend in the first half of 2023 compared to the first two quarters of 2022

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Deals Shaping The Industry, April 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

Dealmaking Quarterly Statistics, Q1 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

More from In Vivo

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Lighting The Way To Anxiety Treatments With No Side Effects

 
• By Ian Taylor

Cutting-edge research is revolutionizing anxiety treatment by targeting specific brain circuits, paving the way for therapies that are free from side effects. This innovative approach promises more efficient and precise medicine, offering hope to millions of people living with anxiety.

Rising Leaders 2025: Stefan König On The Joy Of Watching Talent Grow

 
• By Urtė Fultinavičiūtė

While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.